Angle Portrait PD-L1 Test

Liquid biopsy company Angle has launched the Portrait PD-L1 test for the evaluation of PD-L1 expression on circulating tumor cells. The company is providing the test as a service from its Onc-Adapt GCP-compliant laboratories. Using the company's Parsortix CTC technology, the new assay service features sample stability up to five days post-collection; biomarker-independent harvesting of phenotypically diverse CTCs from a blood sample; identification and enumeration of CTS with accurate assessment of PD-L1 status; and longitudinal monitoring of PD-L1 status over multiple time points including before, during, and after patient treatment, the company said.